Who is sponsoring NCT01424501?

NCT01424501 is sponsored by GlaxoSmithKline.

What condition does NCT01424501 study?

NCT01424501 studies Tuberculosis.

What drugs are being tested in NCT01424501?

Interventions: GSK Biologicals' investigational TB vaccine GSK 692342, Placebo.

What is the status of NCT01424501?

NCT01424501 is currently TERMINATED.

Last reviewed 2018-08-20 · How we verify

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease

NCT01424501 PHASE2 TERMINATED Results posted

This study will assess the safety and immunogenicity of GSK Biologicals' investigational tuberculosis (TB) vaccine (GSK 692342) compared to placebo when administered at 0, 1 months to human immunodeficiency virus (HIV) negative adults who have received treatment for TB disease (denoted TB-treated cohort) or are currently receiving treatment for TB disease (denoted TB-treatment cohort). For comparative purposes, subjects who have never had TB disease (denoted TB-naïve cohort) will also be enrolled.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE2
Status	TERMINATED
Enrolment	142
Start date	Mon Nov 14 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Apr 10 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Tuberculosis

Interventions

GSK Biologicals' investigational TB vaccine GSK 692342
Placebo

Countries

Taiwan, Estonia